Skip to main content
Back
Watch Compare

Fortress Biotech, Inc.

Data quality: 100%
Also listed as FBIOP NASDAQ
FBIO
NASDAQ Manufacturing Chemicals
$2.35
▼ $0.05 (-2.08%)
Mkt Cap: 76.80 M
Price
$2.39
Mkt Cap
76.80 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue declined -2.07% annually over 5 years
ROE of 13.66% — decent returns on equity
Negative free cash flow of -65.78 M
P/E of 11.27 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 11.76%

Growth

Revenue Growth (5Y)
-2.07%
Below sector avg (1.82%)
Revenue (1Y)9.69%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
13.66%
Above sector avg (-53.58%)
ROIC-48.30%
Net Margin10.77%
Op. Margin-111.00%

Safety

Debt / Equity
0.86
Above sector avg (0.30)
Current Ratio2.19
Interest Coverage-6.95

Valuation

PE (TTM|NTM|2027)
11.27 | 4.65 | 4.73
Above sector avg (-1.48)
P/B Ratio1.37
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1366 peers)
Metric Stock Sector Median
P/E 11.3 -1.5
P/B 1.4 1.6
ROE % 13.7 -53.6
Net Margin % 10.8 -41.5
Rev Growth 5Y % -2.1 1.8
D/E 0.9 0.3

Analyst Price Target

2 analysts
Buy
Current
$2.35
+357.4%
Target
$10.75
$4.50
$10.75
$17.00
Forecast
Forward P/E 4.65
Forward EPS $0.51
Est. Revenue 135.31 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 $0.51
-$0.50 – $1.51
 135.31 M 2
FY2026 -$0.70
-$0.70 – -$0.70
 81.74 M 1

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 $0.11 -$0.21 -290.9%
Q32025 -$0.63 $0.11 +117.6%
Q22025 -$0.31 -$0.51 -65.3%
Q12025 -$0.44 -$0.48 -9.1%

ETFs Holding This Stock

BRUSX BRUSX
0.74% weight
DLHAX DLHAX
0.00% weight
DLRHX DLRHX
0.00% weight
DLHIX DLHIX
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 9.69% Revenue Growth (3Y) -13.48%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -2.07% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 63.26 M Net Income (TTM) 6.82 M
ROE 13.66% ROA 3.99%
Gross Margin N/A Operating Margin -111.00%
Net Margin 10.77% Free Cash Flow (TTM) -65.78 M
ROIC -48.30% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.86 Current Ratio 2.19
Interest Coverage -6.95 Asset Turnover 0.37
Working Capital 64.44 M Tangible Book Value 27.19 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 11.27 Forward P/E 4.65
P/B Ratio 1.37 P/S Ratio 1.21
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 0.57 Fwd Earnings Yield 21.51%
FCF Yield -85.64%
Market Cap 76.80 M Enterprise Value 38.36 M
Per Share
EPS (Diluted TTM) -0.07 Revenue / Share 1.96
FCF / Share -2.04 OCF / Share -2.04
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion -965.18%
SBC-Adj. FCF -98.63 M Growth Momentum 11.76

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 63.26 M 57.68 M 84.51 M 75.74 M 68.79 M
Net Income 6.82 M -46.00 M -60.64 M -86.58 M -64.70 M
EPS (Diluted) -0.07 -2.69 -8.47 -0.97 —
Gross Profit — — — — —
Operating Income -70.22 M -110.38 M -142.34 M -203.56 M -188.54 M
EBITDA — — — — —
R&D Expenses — — 106.07 M 134.88 M 128.87 M
SG&A Expenses 96.40 M 87.73 M 94.12 M 113.66 M 86.84 M
D&A — — — — —
Interest Expense 10.11 M 13.53 M 15.32 M 12.48 M 15.31 M
Income Tax -620,000.0 312,000.0 521,000.0 449,000.0 473,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 185.55 M 144.22 M 167.53 M 294.30 M 396.50 M
Total Liabilities 123.37 M 145.87 M 165.94 M 244.28 M 170.63 M
Shareholders' Equity 49.87 M 22.74 M 22.54 M 41.72 M 108.67 M
Total Debt 52.42 M 57.96 M 60.86 M 91.73 M 42.94 M
Cash & Equivalents 79.38 M 57.26 M 80.93 M 178.27 M 305.74 M
Current Assets 123.84 M 90.37 M 117.02 M 230.43 M 346.46 M
Current Liabilities 49.74 M 71.40 M 84.91 M 127.72 M 101.04 M